Yukimasa Makita
Yukimasa Makita has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Satoru Matsumoto
Takeda-CiRA Joint Program, Fujisawa, Japan
3 shared publications- Akitsu Hotta
Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
2 shared publications Hiroyuki Hozumi
T-CiRA discovery, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
2 shared publicationsMika Teratani
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251‑8555, Japan
2 shared publications- Naoto Inukai
T-CiRA discovery, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
2 shared publications Shumpei Murata
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251‑8555, Japan
2 shared publications
Latest Publications
- Open Access
- 22 April 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-9
Intranasal oxytocin suppresses seizure-like behaviors in a mouse model of NGLY1 deficiency
NGLY1 deficiency is a genetic disease caused by biallelic mutations of the Ngly1 gene. Although epileptic seizure is one of the most severe symptoms in patients with NGLY1 deficiency, preclinical studies have not been conducted due to the lack of animal models for epileptic seizures in NGLY1 deficiency. Here, we observed the behaviors of male and female Ngly1−/− mice by video monitoring and found that these mice exhibit spontaneous seizure-like behaviors. Gene expression analyses and enzyme immunoassay revealed significant decreases in oxytocin, a well-known neuropeptide, in the hypothalamus of Ngly1−/− mice. Seizure-like behaviors in Ngly1−/− mice were transiently suppressed by a single intranasal administration of oxytocin. These findings suggest the therapeutic potential of oxytocin for epileptic seizure in patients with NGLY1 deficiency and contribute to the clarification of the disease mechanism.
- 22 April 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-9
Open AccessIntranasal oxytocin suppresses seizure-like behaviors in a mouse model of NGLY1 deficiency
NGLY1 deficiency is a genetic disease caused by biallelic mutations of the Ngly1 gene. Although epileptic seizure is one of the most severe symptoms in patients with NGLY1 deficiency, preclinical studies have not been conducted due to the lack of animal models for epileptic seizures in NGLY1 deficiency. Here, we observed the behaviors of male and female Ngly1−/− mice by video monitoring and found that these mice exhibit spontaneous seizure-like behaviors. Gene expression analyses and enzyme immunoassay revealed significant decreases in oxytocin, a well-known neuropeptide, in the hypothalamus of Ngly1−/− mice. Seizure-like behaviors in Ngly1−/− mice were transiently suppressed by a single intranasal administration of oxytocin. These findings suggest the therapeutic potential of oxytocin for epileptic seizure in patients with NGLY1 deficiency and contribute to the clarification of the disease mechanism.
- Top Cited PapersOpen Access
- 8 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
Genome editing therapy for Duchenne muscular dystrophy (DMD) holds great promise, however, one major obstacle is delivery of the CRISPR-Cas9/sgRNA system to skeletal muscle tissues. In general, AAV vectors are used for in vivo delivery, but AAV injections cannot be repeated because of neutralization antibodies. Here we report a chemically defined lipid nanoparticle (LNP) system which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle by repeated intramuscular injections. Although the expressions of Cas9 protein and sgRNA were transient, our LNP system could induce stable genomic exon skipping and restore dystrophin protein in a DMD mouse model that harbors a humanized exon sequence. Furthermore, administration of our LNP via limb perfusion method enables to target multiple muscle groups. The repeated administration and low immunogenicity of our LNP system are promising features for a delivery vehicle of CRISPR-Cas9 to treat skeletal muscle disorders.
- 8 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Top Cited PapersOpen AccessLow immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
Genome editing therapy for Duchenne muscular dystrophy (DMD) holds great promise, however, one major obstacle is delivery of the CRISPR-Cas9/sgRNA system to skeletal muscle tissues. In general, AAV vectors are used for in vivo delivery, but AAV injections cannot be repeated because of neutralization antibodies. Here we report a chemically defined lipid nanoparticle (LNP) system which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle by repeated intramuscular injections. Although the expressions of Cas9 protein and sgRNA were transient, our LNP system could induce stable genomic exon skipping and restore dystrophin protein in a DMD mouse model that harbors a humanized exon sequence. Furthermore, administration of our LNP via limb perfusion method enables to target multiple muscle groups. The repeated administration and low immunogenicity of our LNP system are promising features for a delivery vehicle of CRISPR-Cas9 to treat skeletal muscle disorders.
- Top Cited PapersOpen Access
- 13 March 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-18
Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping
Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is needed for therapeutic genome editing applications. Here, we develop an extracellular nanovesicle-based ribonucleoprotein delivery system named NanoMEDIC by utilizing two distinct homing mechanisms. Chemical induced dimerization recruits Cas9 protein into extracellular nanovesicles, and then a viral RNA packaging signal and two self-cleaving riboswitches tether and release sgRNA into nanovesicles. We demonstrate efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells, neurons, and myoblasts. NanoMEDIC also achieves over 90% exon skipping efficiencies in skeletal muscle cells derived from Duchenne muscular dystrophy (DMD) patient iPS cells. Finally, single intramuscular injection of NanoMEDIC induces permanent genomic exon skipping in a luciferase reporter mouse and in mdx mice, indicating its utility for in vivo genome editing therapy of DMD and beyond.
- 13 March 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-18
Top Cited PapersOpen AccessExtracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping
Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is needed for therapeutic genome editing applications. Here, we develop an extracellular nanovesicle-based ribonucleoprotein delivery system named NanoMEDIC by utilizing two distinct homing mechanisms. Chemical induced dimerization recruits Cas9 protein into extracellular nanovesicles, and then a viral RNA packaging signal and two self-cleaving riboswitches tether and release sgRNA into nanovesicles. We demonstrate efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells, neurons, and myoblasts. NanoMEDIC also achieves over 90% exon skipping efficiencies in skeletal muscle cells derived from Duchenne muscular dystrophy (DMD) patient iPS cells. Finally, single intramuscular injection of NanoMEDIC induces permanent genomic exon skipping in a luciferase reporter mouse and in mdx mice, indicating its utility for in vivo genome editing therapy of DMD and beyond.
- 29 January 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (4) , 4676-4682
Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts
It has been widely reported that patient-derived tumor xenografts (PDXs) are more similar to tumor tissues than conventional cancer cell lines. Kinetochore‑associated protein 2 (KNTC2) is known to be upregulated specifically in tumor tissues of cancer patients and is recognized as a potential target for cancer therapy. Previously, in vivo antitumor activities of KNTC2 short interfering RNA encapsulated into a lipid nanoparticle (KNTC2‑LNP) were reported in orthotopic hepatocellular carcinoma mouse models. However, it remains unclear whether KNTC2‑LNP exhibits antitumor activities against lung cancer PDXs. In the present study, the antitumor activities of KNTC2‑LNP were clarified in a three-dimensional culture system and a subcutaneous tumor model of lung cancer PDX, LC‑60, which was resistant to erlotinib. Growth inhibitory activities of KNTC2‑LNP were associated with knockdown activities. Furthermore, KNTC2‑LNP also exhibited in vivo antitumor activity against another lung cancer PDX, LC‑45, which was sensitive to erlotinib. These results suggest that KNTC2 is a promising target for patients with lung cancer.
- 29 January 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (4) , 4676-4682
Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts
It has been widely reported that patient-derived tumor xenografts (PDXs) are more similar to tumor tissues than conventional cancer cell lines. Kinetochore‑associated protein 2 (KNTC2) is known to be upregulated specifically in tumor tissues of cancer patients and is recognized as a potential target for cancer therapy. Previously, in vivo antitumor activities of KNTC2 short interfering RNA encapsulated into a lipid nanoparticle (KNTC2‑LNP) were reported in orthotopic hepatocellular carcinoma mouse models. However, it remains unclear whether KNTC2‑LNP exhibits antitumor activities against lung cancer PDXs. In the present study, the antitumor activities of KNTC2‑LNP were clarified in a three-dimensional culture system and a subcutaneous tumor model of lung cancer PDX, LC‑60, which was resistant to erlotinib. Growth inhibitory activities of KNTC2‑LNP were associated with knockdown activities. Furthermore, KNTC2‑LNP also exhibited in vivo antitumor activity against another lung cancer PDX, LC‑45, which was sensitive to erlotinib. These results suggest that KNTC2 is a promising target for patients with lung cancer.
- Open Access
- 1 November 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 493 (1) , 800-806
Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma
- 1 November 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 493 (1) , 800-806
Open AccessAnti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma